The company successfully priced a substantial US$60 million capital raise, demonstrating investor confidence. The offering will fund advancement of NVG-291 through clinical studies, and the company has achieved FDA Fast Track and EMA Orphan Drug designations, indicating regulatory progress and validation of its therapeutic approach for spinal cord injury treatment.
Articles that tag NGEN but are mainly about other companies.
NVG-291 received FDA Fast Track designation and achieved positive Phase 1b/2a results in June 2025, meeting co-primary endpoint with three-fold increase in motor connectivity in chronic SCI patients.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
